Organon & CO

Organon & Co. provides supplemental non-GAAP financial metrics for Q2 2026, detailing Adjusted EBITDA and other key performance indicators ahead of its merger with Sun Pharmaceutical Industries Limited.

Organon & Co. stockholders overwhelmingly approved the merger agreement with Sun Pharmaceutical Industries Limited at a special meeting held on July 23, 2026.

Organon & Co. provides an update on its merger with Sun Pharma, including supplemental disclosures to its proxy statement and details on ongoing litigation.

Organon & Co. stockholders approved an amendment and restatement of the 2021 Incentive Stock Plan, increasing the share pool by 8 million shares.

Organon & Co. reported Q1 2026 revenue of $1.46 billion, down 4% year-over-year, impacted by declines in Women's Health, while announcing a pending merger with Sun Pharmaceutical Industries expected in early 2027.

Sun Pharmaceutical Industries Limited announced a definitive agreement to acquire Organon & Co. for $14.00 per share in an all-cash transaction, valuing Organon at an enterprise valuation of $11.75 billion.

Organon & Co. reported a 2% decrease in Q2 2026 sales, impacted by product mix and foreign exchange, while progressing towards its acquisition by Sun Pharma.

Organon & Co. reported a 4% decrease in Q1 2026 revenue to $1.46 billion, impacted by lower sales of key products, while also announcing a significant divestiture and a proposed acquisition.

Organon reported a significant drop in Q3 net income and EPS, alongside a leadership overhaul and internal investigation findings regarding improper Nexplanon sales practices.

Organon & Co. filed an amended quarterly report, revealing an internal investigation found improper sales practices for Nexplanon, leading to management changes and identified material weaknesses in internal controls.

Organon & Co. filed an amended quarterly report disclosing an internal investigation into improper Nexplanon sales practices, leading to management changes and identified material weaknesses in internal controls.

Organon & Co. reported a 26% drop in second-quarter net income to $145 million, driven by lower sales from loss of exclusivity and increased costs, despite strategic acquisitions and debt reduction efforts.

Organon & Co. reported a 3% decrease in 2025 worldwide sales to $6.2 billion, a $301 million goodwill impairment, and identified material weaknesses in internal controls, while pursuing debt reduction and portfolio adjustments.

Organon & Co. filed an amended annual report disclosing an internal investigation into improper Nexplanon sales practices and material weaknesses in internal controls, leading to executive changes.

Organon & Co. reports a 2% increase in worldwide sales, reaching $6.4 billion in 2024, fueled by growth in women's health and biosimilars portfolios.

Organon & Co.'s 2023 10-K filing reveals a complex financial landscape, marked by modest revenue growth, strategic acquisitions, and ongoing challenges from generic competition and pricing pressures.

Shalini Sharp, a Director at Organon & Co., reported transactions involving phantom stock units, reflecting her participation in the company's Non-Employee Director Savings Plan.

Ramona Sequeira, a Director at Organon & Co., reported a transaction involving phantom stock units, reflecting an economic equivalent of common stock.

Cynthia M. Patton, a Director at Organon & Co., acquired 17,857.143 phantom stock units on June 12, 2026, as part of the company's Non-Employee Director Savings Plan.

Philip Ozuah, a Director at Organon & Co., reported a transaction involving phantom stock units.

Deborah R. Leone, a Director at Organon & Co., reported a transaction involving phantom stock units, reflecting an economic equivalent to common stock.

Rochelle B. Lazarus, a Director at Organon & Co., reported transactions involving phantom stock units, reflecting her beneficial ownership and participation in the company's savings plan.

Organon & Co. has scheduled its annual shareholder meeting for June 10, 2025, outlining proposals including the election of directors, executive compensation, and an amendment to the incentive stock plan.

Organon & Co. invites shareholders to its 2025 Annual Meeting, showcasing strong 2024 business results with revenue growth across all franchises and strategic investments for future growth.

Organon & Co. announces its 2024 Annual Meeting of Shareholders to be held on June 4, 2024, outlining key proposals for voting.

Organon's 2024 proxy statement outlines the company's strategic focus on profitable growth, women's health, and shareholder value, inviting shareholders to the annual meeting on June 4, 2024.

Vanguard Portfolio Management has reported a beneficial ownership of 5.77% in Organon & Co's common stock as of June 30, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.26% of Organon & Co's common stock as of March 31, 2026.

Vanguard Portfolio Management has reported beneficial ownership of 22,052,559 shares, representing 8.47% of Organon & Co's common stock, as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Organon & Co following an internal realignment that disaggregated reporting responsibilities.

The Vanguard Group has disclosed a 13.82% beneficial ownership stake in Organon & Co, holding over 35.9 million shares as of September 30, 2025.

BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, revealing a beneficial ownership of 11.9% in Organon & Co.'s common stock as of March 31, 2025.